Last reviewed · How we verify
NCT00374686
Prophylactic Vs Preemptive Oral Valganciclovir for Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients: A Clinical and Pharmacoeconomic Study
NA trial testing Valganciclovir in Cytomegalovirus Infection in 120 participants. Completed in 1 September 2005.
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 120 |
| Start date | 1 March 2003 |
| Estimated completion | 1 September 2005 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Valganciclovir (VALGANCICLOVIR) — full drug profile →
Conditions studied
- Cytomegalovirus Infection — all drugs for Cytomegalovirus Infection →
Sponsor
Washington University School of Medicine
Who can join
Adults 18 to 85, any sex, with Cytomegalovirus Infection. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
- Primary outcomes included occurrence of CMV infection and disease and response to therapy
Sponsor's own description
This is a study of prophylactic Vs preemptive oral valganciclovir for management of cytomegalovirus infection in adult renal transplant recipients looking at clinical and pharmacoeconomic outcomes
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00374686
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Valganciclovir
Trials testing the same drug.
- NCT07513623 — Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II · Phase 2 · not yet recruiting
- NCT07379203 — ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse · Phase 2 · not yet recruiting
- NCT07079735 — Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant · Phase 2, PHASE3 · recruiting
- NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting
- NCT06034925 — Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients · Phase 4 · completed
Other recruiting trials for Cytomegalovirus Infection
Currently open trials in the same condition.
- NCT06916195 — Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation · recruiting
- NCT05683457 — A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hem · Phase 2 · recruiting
- NCT04706923 — A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection · Phase 2 · recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00374686 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 7 September 2006
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00374686.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing